CUROCOM Co., Ltd. Overview
CreoSG is a micro-cap KOSDAQ company that combines a long-standing but small core-banking software business with an early-stage vaccine and immuno-oncology research programme. The solutions division implements and maintains BANCS-K, a core banking package used by Korean banks and card companies, and accounted for substantially all reported product revenue in FY2025 (KRW 10.86 bn consolidated revenue). The biotechnology division, absorbed through the 2024 merger of subsidiary Immunovax Bio (formerly Sumagen), owns the recombinant vesicular stomatitis virus (rVSV) vector platform SUV-MAP and the whole-killed HIV vaccine candidate SAV001, which completed a US Phase 1 trial and has been in Phase 2 preparation since 2024. The company has reported operating losses in every year from FY2021 to FY2025, has relied on rights offerings, convertible bonds and capital reductions to sustain equity, and sits inside a complex QCP Group cross-shareholding structure with material related-party lending.
Company's own description
Company-provided summaries reproduced by data vendors (WiseReport, 3-Sep-2026; FnGuide; StockDigging) describe CreoSG as a company founded in 1997 for software development and biotechnology, listed on KOSDAQ in 2002, which strengthened its solutions business through a 2005 merger and added real-estate operations in 2024. It reports three activity areas:
-
Solutions business: supply, implementation and consulting of the BANCS-K core banking package (framework and core account-processing functions) for financial institutions and public bodies; system migration; extension of financial-sector experience into manufacturing and service clients.
-
Bio business: development of vaccines for infectious diseases (AIDS, COVID-19 and others) using a proprietary general-purpose development platform (SUV-MAP), and, since 2024, immuno-oncology research.
-
Real-estate operation and rental management: conducted by subsidiary Creo Estate (크레오에스테이트), established April 2024.
A legacy distribution line (computers, monitors, SSDs, printers, peripherals) remains in the description but is immaterial: AlphaSquare's revenue-mix table (FY2025) shows software development and maintenance at 99.7% and computer/peripheral distribution at 0.3%.
Business model and revenue model
| Revenue type | Business | Characterisation | Evidence |
|---|---|---|---|
| Project/implementation revenue | Solutions | Fixed-scope SI projects for banks (core-banking build, migration, enhancement) | H1 2026 growth attributed to new projects for Woori Bank, Hana Bank, National Forestry Cooperative Federation (WiseReport, 3-Sep-2026) |
| Maintenance (recurring service) | Solutions | Ongoing maintenance of installed BANCS-K systems | "S/W development and maintenance" line, 99.7% of FY2025 mix (AlphaSquare) |
| Subcontract IT infrastructure | Solutions | Infrastructure supply under prime contractors | KRW 1.99 bn Samsung SDS contract, May-2026 to Aug-2027 (TopStarNews, May-2026) |
| Licensing / milestones | Bio | None reported to date; management targets technology transfer after Phase 2 | Asiae, 15-Oct-2024 and 8-Sep-2026 |
| Product sales (health functional food) | Bio-adjacent | MUSCLO (CAF-based) supply agreements announced 2025; revenue contribution not separately disclosed | Asiae, 14-Mar-2025 |
| Rental income | Real estate | Creo Estate operation and rental management | StockDigging; WiseReport |
A Saramin profile displays a "business-segment weighting" of Solutions 67.9%, Bio 20.4%, Other 12.5%; the basis (revenue, headcount or assets) and period are not stated, so it should not be read as a confirmed revenue split.
Value-chain position, customers and end-markets
Solutions: CreoSG is a package-software vendor and implementer positioned below large Korean system integrators (it also acts as a subcontractor to Samsung SDS). A May-2026 Pinpoint News article states the company supplies core-banking solutions to 14 domestic banks and 3 credit-card companies; this figure is not confirmed in a primary filing reviewed.
Bio: CreoSG is a discovery and early-clinical developer that outsources manufacturing (Naobios, France, BSL-3 CDMO), clinical operations (Fortrea, CRO) and preclinical studies (International Vaccine Institute, Gyeongbuk Institute for Bio Industry), consistent with the CEO's statement in September 2026 that the company relies on external infrastructure rather than building its own (Asiae, 8-Sep-2026).
End-markets: Korean banking IT (domestic); infectious-disease vaccines (global public-health purchasers and governments); oncology (global pharma partners); health functional foods (Korea, Southeast Asia, China, Japan).
Independent characterisation
On the evidence, CreoSG is functionally a small, loss-making Korean banking-software contractor (revenue around KRW 11–12 bn on a trailing basis) carrying an early-stage biotech option. The bio business generates no disclosed licensing revenue, and its flagship asset has been "preparing for Phase 2" since at least April 2024. Reported net losses have been driven as much by non-operating items (equity-method losses, CB valuation changes, related-party financial exposures) as by operations. The equity story depends on capital-market access and on group-level financing arrangements with Curo Holdings and GNCO.
Strategy
Stated strategy themes
Bio-centred restructuring (Mar-2024): rename to CreoSG; move bio programmes (SUV-MAP, HIV vaccine) under the listed parent to speed commercialisation and ease partnerships with leading biotech companies (Edaily, 29-Mar-2024).
Platform expansion from vaccines into immuno-oncology: use SUV-MAP as an oncolytic vector, alone and in combination with tumour-matrix-loosening technology; pursue co-development or licensing with multinational pharma (Asiae, 8-Sep-2026).
Market-led clinical prioritisation: move vaccine candidates with existing markets (Hantavirus, SFTS) into clinical trials to generate revenue (CEO, Asiae, 8-Sep-2026).
Geographic targeting: MERS (Saudi Arabia, Middle East, Southeast Asia), Zika (Brazil), Ebola (Africa, Europe) (CEO, Asiae, 8-Sep-2026).
Asset-light R&D: rely on IVI, universities, national R&D programmes and CDMOs/CROs until profitability (CEO, Asiae, 8-Sep-2026).
Monetisation of bio assets: in Oct-2025 the company said it was pursuing an overseas sale of bio business assets, including Sumagen Canada (Asiae, 1-Oct-2025).
Solutions: extend financial-sector experience to manufacturing and service clients; system migration (FnGuide summary).
Initiatives in the last 24 months
| Date | Initiative | Status / outcome | Source |
|---|---|---|---|
| Apr-2024 | Creo Estate real-estate subsidiary | Operating | Saramin |
| Apr-2024 | Naobios manufacturing contract for SAV001 Phase 2 | In production as of Oct-2025 | Asiae |
| Jul–Sep-2024 | Absorption of Immunovax Bio | Completed Sep-2024 | Asiae; Saramin |
| Aug–Oct-2024 | Immuno-oncology team and research centre | Team head hired; centre build reported | Asiae |
| Sep–Nov-2024 | KRW 30 bn rights offering | Completed | Asiae |
| Nov-2024 / Oct-2025 | Alteogen MOU and MTA | Joint formulation research ongoing | Asiae |
| Dec-2024 / Mar-2025 | CAF/MUSCLO health-food business | Distribution agreements announced; revenue targets not met in FY2025 | Asiae |
| H1-2025 | KRW 10 bn third-party offering | Failed | Asiae, 1-Oct-2025 |
| Oct-2025 / Mar-2026 | Capital reduction and share consolidation | Completed (relisted 12-May-2026) | Asiae; Datatooza |
| Apr–Aug-2026 | Review of CB acquisition and management participation in OCP Bio M | Terminated 31-Aug-2026 after the valuation report was not issued and due diligence found material negative financial conditions | GoInsider (DART summary) |
| Jun-2026 | KDCA Marburg vaccine project | Participating | Asiae |
| Oct-2026 | Debt-to-equity swap into Curo Holdings | Expected closing 23-Oct-2026 | Digital Today |
Sustainability/ESG commitments and cost programmes
None publicly disclosed in sources reviewed.
Medium-term financial targets / guidance
The company has not issued formal financial guidance. The only quantified targets found are the March-2025 MUSCLO revenue targets (KRW 10 bn in 2025, KRW 80 bn in 2026, KRW 120 bn in 2027, KRW 200 bn+ per year from 2028), stated in a press article rather than a regulatory filing (Asiae, 14-Mar-2025). FY2025 reported consolidated revenue (KRW 10.86 bn, 99.7% software) indicates the 2025 target was not achieved.
Products & Services
Solutions segment
| Offering | Description | Target customer | Launch / status | Pricing model | Source |
|---|---|---|---|---|---|
| BANCS-K (Banking Automation & Network Control System – Korea) | Core banking package providing framework and core account-processing functions; described by the company as applied at Korean financial institutions for more than 15 years | Banks, card companies, cooperative financial institutions, public bodies | In market since at least the mid-2000s | Project + maintenance fees (not disclosed) | JobKorea profile; AlphaSquare |
| System migration | Migration of legacy banking systems | Financial institutions | Ongoing | Project-based | FnGuide business summary |
| SI / SM / DB construction | System integration, system management and maintenance, database build | Financial, manufacturing and service clients | Ongoing | Project / time-and-materials | Saramin profile |
| IT consulting (IT strategy, ISP, corporate growth strategy) | Consulting from strategy through solution delivery | Enterprises | Described as "recently started" in JobKorea profile | — | JobKorea profile |
| IT infrastructure supply | Infrastructure supply under Samsung SDS prime contract, KRW 1.99 bn, 26-May-2026 to 25-Aug-2027 (18.32% of FY2025 revenue) | Samsung SDS (prime contractor) | 2,026 | Contract value | TopStarNews, May-2026 |
| Computer and peripheral distribution | LED/TV monitors, SSDs, PCs, laptops, printers, MFPs, scanners | Corporate buyers | Legacy; 0.3% of FY2025 revenue | Resale margin | Investing.com; Saramin |
Independent note: The name "BANCS" matches the core-banking product line originally developed by Australia's Financial Network Services and later owned by Tata Consultancy Services (TCS BaNCS). The 2005 merger with "FnS.com" suggests a historical link, but the licensing relationship between CreoSG and TCS is not confirmed in the sources reviewed.
Bio segment — platform
| Asset | Description | Status | Source |
|---|---|---|---|
| SUV-MAP (Sumagen rVSV Multifunctional All Platform) | Attenuated recombinant vesicular stomatitis virus vector. Target-antigen genes are inserted into the vector and the recombinant virus is grown in cell culture. The company says it can identify a vaccine candidate within about 5 months of obtaining viral information and reach GMP production within about 6 months. Designed to be temperature-sensitive so replication is limited in humans. Interferon-suppression function weakened for oncology use. | Platform launched 2024; EPO grant Oct-2024 (valid in 17 EU unitary-patent states); company states patents in more than 10 countries | Asiae, 29-Jul-2024, 22-Oct-2024, 23-Oct-2024, 8-Sep-2026 |
Bio segment — pipeline (product by product)
| Candidate | Indication | Technology | Stage (latest disclosed) | Partners | Key disclosed data / events | Source |
|---|---|---|---|---|---|---|
| SAV001 / SAV001-H | HIV/AIDS (therapeutic and preventive intent) | Whole-killed HIV vaccine (chemically and radiation inactivated) | Phase 1 completed in US (4 California hospitals, HIV subtype B carriers); Phase 2 clinical material in production; FDA Type C meeting agreement on Phase 2 synopsis | Naobios (CDMO, France), Fortrea (CRO), Dr. Onesmo Mpanju (former FDA CBER reviewer, consultant) | Antibody titres rose up to 512-fold and were maintained for 12 months in Phase 1 per company; COVID-19 interrupted CMO capacity; production "progressing" as of Oct-2025 | Asiae, 22-Apr-2024, 28-Aug-2024, 15-Oct-2024, 13-Oct-2025 |
| SUV-MAP HIV boost (combination regimen) | HIV/AIDS | SAV001 prime + VSV-vector boost | Efficacy evaluation (preclinical) | — | Announced May-2024 | Asiae, 9-May-2024 |
| VSV-MERS | MERS-CoV | SUV-MAP with MERS spike/envelope protein | Preclinical; patents: Korea (decision 1-Sep-2025), Saudi Arabia (Mar-2026), Canada (Jun-2026) | IVI; University of Western Ontario (Prof. Kang Chil-yong) | Company is planning a commercialisation roadmap; Middle East and Southeast Asian interest cited by CEO | Asiae, 1-Sep-2025, 24-Mar-2026, 26-Jun-2026, 8-Sep-2026 |
| VSV-Zika | Zika virus | SUV-MAP with Zika envelope protein | Preclinical; Korean patent registered Mar-2025 | IVI | Brazil interest cited by CEO | Asiae, 1-Sep-2025, 8-Sep-2026 |
| VSV-COVID-19 | SARS-CoV-2 | SUV-MAP | Preclinical (first SUV-MAP vaccine; animal efficacy reported superior to comparators by company) | IVI; Gyeongbuk Vaccine Commercialisation Center | Patents obtained per company | Asiae, 23-Oct-2024 |
| SFTS + HFRS bivalent vaccine | Severe fever with thrombocytopenia syndrome and haemorrhagic fever with renal syndrome (Hantavirus) | SUV-MAP | Candidate identified under national project; CEO targets clinical entry | Gyeongbuk Institute for Bio Industry national project; IVI | Company describes it as the first bivalent candidate for both diseases | Asiae, 29-Jul-2024, 4-Sep-2024, 8-Sep-2026 |
| VSV-Ebola (Zaire) | Ebola | SUV-MAP with Ebola glycoprotein | Candidate secured (preclinical) | — | Announced 11-Aug-2026 | Asiae, 11-Aug-2026 |
| VSV-Marburg | Marburg virus disease | Attenuated recombinant VSV | Co-research institution in KDCA project for candidate and assay development | Korea Disease Control and Prevention Agency (KDCA) | Announced 2-Jun-2026 | Asiae, 2-Jun-2026 |
| Crimean-Congo haemorrhagic fever, Nipah, Lassa | High-risk emerging infections | SUV-MAP | Planned/early research | — | Listed as expansion targets | The Bell, 6-Aug-2026; Asiae, 22-Oct-2024 |
| Rotavirus and dengue vaccines | Rotavirus, dengue | AI-based protein design + SUV-MAP | Early research | — | Announced in Sep-2026 interview | Asiae, 8-Sep-2026 |
| SUV-MAP oncolytic immunotherapy | Solid tumours (breast, colorectal, pancreatic, skin targeted) | Interferon-sensitive VSV vector that replicates selectively in tumour cells; cytokine-gene payloads; combination with tumour-matrix-loosening technology | Mechanism-of-action confirmation and candidate optimisation (preclinical) | Alteogen (ALT-B4 hyaluronidase; MOU Nov-2024, MTA 2-Oct-2025) | In-house immuno-oncology research centre built 2024 | Asiae, 6-Nov-2024, 29-Oct-2024, 2-Oct-2025, 8-Sep-2026 |
| Inferrex antibiotic | Drug-resistant S. aureus ("superbug") | Small-molecule/antibiotic (details not disclosed) | Research; Japanese patent | — | — | AlphaSquare; WiseReport |
Health functional foods (bio-adjacent)
| Product | Description | Partners | Status | Source |
|---|---|---|---|---|
| MUSCLO (머슬로) | Muscle-growth drink and powder based on CAF (Cell Activation Factor), derived from brown-algae polyphenol Seapolynol; company states CAF obtained US FDA New Dietary Ingredient notification | Hepatol (rights holder; MOU Dec-2024 and supply agreement); Human Cell Medical (Southeast Asia), Shandong SC Technology Innovation (China), Elumild (Japan) | Company announced Asian distribution start in Mar-2025 with targets of KRW 10 bn revenue in 2025, KRW 80 bn in 2026, KRW 120 bn in 2027 and KRW 200 bn+ annually from 2028 | Asiae, 27-Dec-2024 and 14-Mar-2025 |
Analyst note: Total consolidated FY2025 revenue was KRW 10.86 bn, with 99.7% attributed to software. The MUSCLO revenue targets were therefore not met in FY2025, and no MUSCLO revenue line is visible in disclosed data.
Financial Narrative
Accounting basis: K-IFRS consolidated. FY2024 and FY2025 figures use final (audited) values reproduced by AlphaSquare and Hankyung Korea Market. Preliminary disclosures differed:
Income statement (chartable)
Sources and methods: FY2022–FY2025 revenue, operating income and net income from AlphaSquare (DART). FY2021 revenue derived from FY2022 revenue and Hankyung's reported FY2022 growth of 13.27%; FY2021 operating and net income derived from Hankyung's FY2021 margins (-52.62%, -190.57%). Gross profit FY2021–FY2023 from Hankyung (reported in KRW mn); FY2024–FY2025 derived from Hankyung gross margins. EBITDA FY2025 from WiseReport. EPS FY2021–FY2024 from Hankyung on the pre-consolidation basis (par KRW 500); FY2025 EPS from WiseReport on the current basis. The restated EPS row multiplies pre-2025 values by 10 to reflect the 2:1 and 5:1 consolidations (derived; approximate). Diluted EPS: not disclosed in sources reviewed. Dividends: none paid (Simply Wall St).
Margins and growth (chartable)
Source: Hankyung Korea Market financial summary (FY2021–FY2025). EBITDA margin FY2025 derived (-5.840 / 10.861).
Revenue CAGR FY2021–FY2025: approximately 5.9% per year (derived: (10.861 / 8.635)^(1/4) − 1). The growth is not steady: two of the four years show declines, and FY2025 recovered from a weak FY2024 base.
Recent quarters (chartable)
Source: AlphaSquare (DART quarterly data). Q1 FY2026 also confirmed by AWAKEPLUS (revenue KRW 2.6 bn, operating loss KRW 0.8 bn, net loss KRW 1.9 bn; quarterly report filed 15-May-2026).
Trailing four quarters to 30-Jun-2026 (derived): revenue KRW 11.912 bn; operating loss KRW -3.807 bn; net loss KRW -3.175 bn.
H1 FY2026 vs H1 FY2025 (WiseReport, 3-Sep-2026): revenue +22.1%; operating loss reduced 73.3%; net loss reduced 97.9%. H1 FY2026 revenue was KRW 5.812 bn (derived from Q1 + Q2) against approximately KRW 4.76 bn in H1 FY2025 (AKGround, citing the H1 FY2025 report). H1 FY2025 operating loss was KRW -3.55 bn (same source).
Balance sheet (chartable)
Sources and methods: Total assets FY2024–FY2025 from the 13-Feb-2026 DART results disclosure (Digital Today/Nate). FY2025 total equity of KRW 47.214 bn from the "own capital" figure in the 15-Oct-2026 DART acquisition disclosure; equity attributable to owners and share capital from the 13-Feb-2026 disclosure. FY2024 share capital of about KRW 97.6 bn and impairment ratio of 47.7% from Asiae, 1-Oct-2025; FY2024 equity derived as capital × (1 − 0.477) (approximate). Liabilities derived as assets minus equity. BPS from Hankyung (FY2021–FY2024) and WiseReport (FY2025). Goodwill and intangibles, short/long-term debt split, net debt and working capital: not publicly disclosed in sources reviewed. A data vendor (AlphaSpread) reports total debt of KRW 25.06 bn at the latest reporting date, without stating the date or composition.
Latest balance sheet (H1 FY2026, AlphaSquare): total assets KRW 91.396 bn; liabilities 47.98% and equity 52.02% of assets (implying equity of about KRW 47.55 bn and liabilities of about KRW 43.85 bn, derived).
Cash flow (chartable)
Cash-flow statements were not available in the sources reviewed. Dividends: none (Simply Wall St). Treasury shares: 40,120 (0.20%) as of 28-Sep-2026 (WiseReport); no buyback programme found.
Ratios (chartable)
Sources: ROE and debt ratio FY2025 from AlphaSquare (FnGuide shows ROE of -29.01% on a different, likely trailing, basis). ROA and asset turnover FY2025 derived using average FY2024–FY2025 total assets (KRW 90.12 bn). P/B from Hankyung. ROIC, current ratio, interest coverage and cash conversion cycle: not publicly disclosed in sources reviewed; interest coverage is not meaningful because operating income is negative in every year.
Commentary on trends, inflections and drivers
Revenue. Revenue sat between KRW 8.2 bn and KRW 9.8 bn from FY2021 to FY2024. The FY2024 decline (-16.4%) was attributed by the company to lower solutions revenue (Datatooza, 12-Feb-2025). The FY2025 rebound (+33.2%) was attributed to higher revenue in the solutions division and subsidiaries (13-Feb-2026 disclosure). H1 FY2026 growth (+22.1%) came from new projects with Woori Bank, Hana Bank and the National Forestry Cooperative Federation (WiseReport). The business is project-driven, so quarterly revenue moves with contract timing.
Gross margin. Gross margin improved from 23.8% (FY2022) to 34.8% (FY2025). The disclosed data does not explain the cause; a higher maintenance share or better project pricing are possible explanations but are not confirmed.
Operating losses. Operating losses have been large relative to revenue in every year (margins between -38% and -69%). The FY2024 widening was attributed to development costs for producing Phase 2 HIV-vaccine clinical material (Datatooza, 12-Feb-2025). Because pre-Phase 3 development costs must be expensed, the merger of Immunovax Bio in 2024 moved these costs directly into CreoSG's income statement and reduced equity (Asiae, 1-Oct-2025). The sharp narrowing of the Q2 FY2026 operating loss to KRW -0.14 bn is the main inflection in the data. Whether it reflects lower bio spending (for example, timing of Naobios production payments) or solutions operating leverage is not disclosed.
Net losses. Net losses exceeded operating losses by KRW 7–12 bn per year from FY2021 to FY2024, which indicates large non-operating charges. The FY2025 improvement was attributed to valuation gains on convertible bonds held by the company and smaller equity-method losses (13-Feb-2026 disclosure). Q2 FY2026 showed a net profit of KRW 1.78 bn despite an operating loss, again pointing to non-operating gains; the composition is not disclosed in the sources reviewed. These items are tied to the group's cross-holdings and CB instruments and are not recurring operating earnings.
Capital structure. Equity has been maintained through repeated issuance (rights offerings, third-party allotments, CBs) and two share consolidations. The capital-impairment ratio rose to 53.0% at H1 FY2025 and triggered an "investment caution" designation. The 2:1 capital reduction cut share capital from about KRW 97.6 bn to KRW 48.8 bn and used the reduction to offset accumulated deficits, bringing the impairment ratio to 5.14% at FY2025 year-end. This is an accounting remedy; it did not add cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products/services | Notes |
|---|---|---|---|
Solutions | Core-banking package sales, SI, SM, IT consulting, legacy hardware distribution | BANCS-K; system migration; IT strategy/ISP consulting | Majority of revenue; H1 2026 growth driver |
Bio | Vaccine and immuno-oncology R&D (in-house since 2024 merger) plus subsidiaries Sumagen Canada and Inferrex | SUV-MAP platform; SAV001; MERS, Zika, SFTS/HFRS, COVID-19, Ebola, Marburg candidates; oncolytic VSV | No disclosed licensing revenue |
Real estate (Other) | Creo Estate (est. Apr-2024) | Property operation and rental management | Revenue not separately disclosed |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue (KRW Bn) | 9.756 | 8.157 | 10.861 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansProduct Lines
| Product line | Share of revenue (%) |
|---|---|
Software development and maintenance (Solutions) | 99.7 |
Computers and peripherals (Distribution) | 0.3 |
Group Entities
| Entity | Relationship | Activity | Source |
|---|---|---|---|
Sumagen Canada Inc. | Consolidated subsidiary | Overseas vaccine R&D; MERS patent holder in Canada | WiseReport; The Bell, 6-Aug-2026 |
Inferrex | Consolidated subsidiary | Antibiotic research for drug-resistant bacteria; Japanese patent on S. aureus therapy | WiseReport; AlphaSquare |
Creo Estate (크레오에스테이트) | Consolidated subsidiary | Real estate operation | WiseReport; Saramin |
GNCO Co., Ltd. (지엔코, KOSDAQ 065060) | Investee; CreoSG stake 46.29% after Sep-2025 CB call-option exercise; 37.70% shown in a May-2026 holding record | Fashion apparel | Digital Today, 17-Sep-2025; GoInsider |
Curo Holdings Co., Ltd. (KOSDAQ 051780) | Largest shareholder of CreoSG; CreoSG holds 9.96%, rising to 36.85% on completion of the Oct-2026 debt-to-equity swap | Coffee distribution; group holding | IB Tomato, 1-Jul-2026; Digital Today, 15-Oct-2026 |
Q Capital Partners (KOSDAQ 016600) | Affiliate; holds 3.96% of CreoSG (Aug-2026) and is a lender to Curo Holdings | Venture capital | GoInsider; IB Tomato |
K Partners (케이파트너스) | Second-largest shareholder of CreoSG (2024–2025); owner-family vehicle | Holding | Asiae, 1-Oct-2025; Etoday, 19-Aug-2026 |
Financial Analysis
| Item | Preliminary disclosure | Final (used below) | Source |
|---|---|---|---|
FY2024 operating loss (KRW Bn) | -5.610 | -5.654 | Datatooza/Edaily, 12-Feb-2025; AlphaSquare |
FY2024 net loss (KRW Bn) | -13.024 | -13.879 | Same |
FY2025 operating loss (KRW Bn) | -6.099 | -6.409 | Digital Today/Nate, 13-Feb-2026; AlphaSquare |
FY2025 net loss (KRW Bn) | -8.467 | -8.550 | Same |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 8.635 | 9.781 | 9.756 | 8.157 | 10.861 |
Gross profit (KRW Bn) | 2.715 | 2.331 | 2.401 | 2.504 | 3.776 |
Operating income (KRW Bn) | -4.544 | -6.139 | -3.735 | -5.654 | -6.409 |
EBITDA (KRW Bn) | — | — | — | — | -5.840 |
Net income (KRW Bn) | -16.456 | -13.061 | -13.494 | -13.879 | -8.550 |
EPS basic, as reported (KRW) | -118 | -83 | -93 | -83 | -441 |
EPS basic, restated to current share basis (KRW) | -1,180 | -830 | -930 | -830 | -441 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | -12.02 | 13.27 | -0.26 | -16.39 | 33.15 |
Gross margin (%) | 31.43 | 23.83 | 24.61 | 30.70 | 34.77 |
Operating margin (%) | -52.62 | -62.77 | -38.28 | -69.31 | -59.01 |
EBITDA margin (%) | — | — | — | — | -53.77 |
Net margin (%) | -190.57 | -133.53 | -138.31 | -170.14 | -78.72 |
Income Statement
| Metric | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|---|
Revenue (KRW Bn) | 2.886 | 3.214 | 2.631 | 3.181 |
Operating income (KRW Bn) | -0.922 | -1.936 | -0.812 | -0.137 |
Net income (KRW Bn) | -0.909 | -2.146 | -1.904 | 1.784 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | — | — | — | 91.503 | 88.742 |
Total equity incl. NCI (KRW Bn) | — | — | — | 51.050 | 47.214 |
Equity attributable to owners (KRW Bn) | — | — | — | — | 46.292 |
Total liabilities (KRW Bn) | — | — | — | 40.453 | 41.528 |
Share capital (KRW Bn) | — | — | — | 97.601 | 48.801 |
Capital impairment ratio (%) | — | — | — | 47.7 | 5.14 |
BPS as reported (KRW) | 379.82 | 306.83 | 251.56 | 261.40 | 2,430 |
BPS restated to current share basis (KRW) | 3,798 | 3,068 | 2,516 | 2,614 | 2,430 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis (Annual)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Instrument by Date
| Date | Instrument | Amount | Terms | Source |
|---|---|---|---|---|
Nov-2024 | Shareholder rights offering (planned KRW 30 bn, 41 mn shares at expected KRW 732) | — | Final price implied at about KRW 538 by the group's subscription (derived: 7.5 bn / 13,949,238 shares) | Asiae, 4-Sep-2024 and 7-Nov-2024 |
H1 2025 | Third-party offering (planned KRW 10 bn) | Not completed (investors withdrew/changed) | — | Asiae, 1-Oct-2025 |
Sep-2025 | Small public offering to K Partners | KRW 0.99999995 bn | Subscription 15-Sep, payment 19-Sep-2025; 6-month lock-up | Digital Today, 3-Sep-2025 |
Nov-2025 | Private CB (23rd series, inferred numbering) | KRW 2.0 bn | 0% coupon; 8% YTM (quarterly compounding); KRW 0.968 bn working capital, KRW 1.032 bn debt repayment | Edaily, Nov-2025 |
May-2026 | 24th private CB | — | 0% coupon; for working capital | GoInsider (DART summaries 18/22-May-2026) |
Jul-2026 | CB conversion | 335,664 shares at KRW 3,575 (about KRW 1.2 bn, derived) | Listed 21-Jul-2026 | TopStarNews, Jul-2026 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | — | — | — | -17.46 |
ROA (%) | — | — | — | -9.49 |
Debt ratio, liabilities/equity (%) | — | — | — | 88.33 |
Asset turnover (x) | — | — | — | 0.12 |
Price / book at year-end (x) | 2.98 | 2.05 | 2.17 | — |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 9.756 | 8.157 | 10.861 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Close | KRW 2,975 | AlphaSquare |
52-week range (adjusted) | KRW 2,780–12,800 (note: an intraday low of KRW 2,720 was printed on 19-Oct-2026, so the displayed low appears to use closing prices or lag) | AlphaSquare |
Market cap | KRW 59.1 bn (derived) | Derived |
Shares outstanding | 19,856,196 | TopStarNews |
Daily volume (19-Oct-2026) | 39,224 shares | AlphaSquare |
Short interest | 0 shares (15-Oct-2026) | AlphaSquare |
Beta (1-year) | 0.61 (FnGuide, earlier period) | FnGuide |
Dividend history and policy | No recent dividends | Simply Wall St |
Buyback authorisations | None found; 40,120 treasury shares | WiseReport |
Credit ratings (Moody's/S&P/Fitch) | Not rated | — |
Korean agency ratings | None found | — |
Capital Markets Data (KRW)
| Metric | Jun-2026 | Jul-2026 | Aug-2026 | Sep-2026 | Oct-2026 |
|---|---|---|---|---|---|
Reference close (KRW) | 8,000 | 8,740 | 6,460 | 3,415 | 2,975 |
Valuation Multiples
| Multiple | CreoSG | Basis |
|---|---|---|
P/S | 4.96x | Market cap / trailing revenue KRW 11.91 bn |
P/B | 1.22x | FY2025 BPS KRW 2,430 (WiseReport); AlphaSquare displays 2.01x on its own basis |
EV/Sales | Not computed | Cash balance not disclosed |
Capital Instruments
| Instrument | Issued | Amount | Key terms | Status | Source |
|---|---|---|---|---|---|
20th CB | Aug-2021 | — | — | — | Saramin |
21st CB | Mar-2022 | — | — | — | Saramin |
22nd CB | Aug-2023 (dated by sequence) | — | — | — | Saramin |
23rd CB (numbering inferred) | Nov-2025 | KRW 2.0 bn | 0% coupon; 8% YTM | Partly converted (335,664 shares at KRW 3,575, Jul-2026) | Edaily; TopStarNews |
24th CB | May-2026 | — | 0% coupon; private | Outstanding | GoInsider |
Total debt (latest report) | — | KRW 25.06 bn | Composition not stated | — | AlphaSpread |
Analyst Conclusions
Management guidance
No formal financial guidance. Management's qualitative priorities (Asiae, 8-Sep-2026): start SAV001 Phase 2 once clinical material is complete; move Hantavirus and SFTS vaccine candidates into clinical trials; develop oncolytic SUV-MAP to a stand-alone candidate and seek partners; pursue overseas markets for MERS, Zika and Ebola vaccines; build in-house capacity only after profitability.
Consensus
No sell-side coverage; no consensus estimates.
Bull case
-
Solutions momentum may reach break-even. Revenue grew 33.15% in FY2025 and 22.1% in H1 FY2026, and the Q2 FY2026 operating loss narrowed to KRW 0.14 bn. A full year near operating break-even would remove the main source of equity erosion.
-
SAV001 is a differentiated clinical asset. Phase 1 data (company-reported antibody increases maintained for 12 months), an FDA-agreed Phase 2 synopsis and engaged CDMO/CRO partners mean a Phase 2 start is plausible; any licensing deal would be large relative to a KRW 59 bn market cap.
-
Platform IP and public funding. Granted patents in Europe, Korea, Saudi Arabia and Canada, plus KDCA and IVI collaborations, give SUV-MAP credibility for government-funded programmes with low capital needs.
Bear case
-
Related-party exposure dominates the balance sheet risk. KRW 9.15 bn of loans to the controlling shareholder were partly converted into KRW 8.09 bn of illiquid parent equity (17.14% of CreoSG's equity), deepening a circular structure that already includes GNCO.
-
Funding dependence and dilution. A failed KRW 10 bn offering, a KRW 1 bn related-party top-up, recurring CBs and two share consolidations show that capital is scarce; Phase 2 HIV trials would require more.
-
Credibility gap. The MUSCLO revenue targets were not met, SAV001 Phase 2 has been "imminent" since 2024, the OCP Bio M initiative was reversed, and an unfaithful-disclosure designation was reported.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Closing of Curo Holdings debt-to-equity swap | 23-Oct-2026 | Size of related-party exposure; voting-rights questions |
| Q3 FY2026 report | Mid-Nov-2026 | Whether Q2's narrower operating loss is sustained |
| SAV001 Phase 2 IND filing / first patient | Not dated | Primary bio re-rating event |
| FY2025-type annual results for FY2026 | Feb–Mar 2027 | Capital-impairment test; going-concern language |
| New CB issuance or conversions | Ongoing | Dilution |
| Pledge enforcement or largest-shareholder change filings | Ongoing | Control stability |
| Bio-asset sale (Sumagen Canada) | Not dated | Possible non-dilutive cash |
| New bank core-system contracts | Ongoing | Solutions revenue visibility |
Concluding analyst verdict
CreoSG is two businesses joined to a group-financing structure. The first is a small but real Korean core-banking software and services operation that grew revenue to KRW 10.86 bn in FY2025 and kept growing in H1 FY2026, with improving gross margins and a sharply narrower Q2 FY2026 operating loss. On its own, that business would be a modest, project-driven contractor worth roughly what the market currently pays, and the data suggests it is moving towards operating break-even.
The second is a biotechnology option built around the SUV-MAP rVSV platform and the SAV001 whole-killed HIV vaccine. The scientific assets have genuine elements, including completed Phase 1 work, granted patents across several jurisdictions, and collaborations with IVI, KDCA, Alteogen, Naobios and Fortrea. But the flagship programme has been in Phase 2 preparation for more than two years without a disclosed start date, the pipeline is broad relative to resources, and the health-food targets publicised in 2025 were not realised.
The decisive factor for an investor is governance and capital allocation. Losses have been absorbed through rights offerings, convertible bonds, a capital reduction and a share consolidation, while the listed company has lent money to its controlling shareholder and is now converting KRW 8.09 bn of that lending into a 36.85% stake in the same shareholder. Pledged shares, a reported unfaithful-disclosure designation and a reversed acquisition review add to the concern. These features make reported net income, book value and even control of the company less reliable than the headline numbers imply.
Verdict: CreoSG is a high-risk, speculative micro-cap. Operating improvement in the solutions business is a positive, but it is outweighed by related-party financial exposure, dependence on dilutive financing and the absence of a dated clinical catalyst. Any engagement should be conditioned on audited FY2026 results, clarity on the Curo Holdings transaction and a confirmed SAV001 Phase 2 start.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation | Source |
|---|---|---|---|---|---|
Dr. Lee Sang-gyun (이상균) | CEO and representative director | Since Mar-2024 | Led bio research at subsidiary Sumagen for many years; developer of SUV-MAP | Not disclosed (Korean rules require individual disclosure only above KRW 500 mn) | Edaily, 29-Mar-2024; Inews24, 29-Mar-2024 |
Dr. Son Ho-seon (손호선) | Head of immuno-oncology R&D | Since Aug-2024 | BS/MS Seoul National University; PhD in developmental and neuroendocrinology; LG Chem drug-discovery team (CDK4 inhibitor); KCDC vaccine research division from 2011 (smallpox vaccine) | — | Asiae, 19-Aug-2024 |
Joong-Ki Cho; Jong-Sung Park | Listed as key executives | Titles not disclosed | — | — | PatSnap company profile |
“—” = not publicly disclosed.
Governance Overview
| Item | Detail | Source |
|---|---|---|
Outside directors | 2 (both attended board meetings on 10-Apr-2026 and 15-Oct-2026) | Digital Today, 10-Apr-2026 and 15-Oct-2026 |
Audit function | "Auditor (audit committee member)" attended board meetings; whether a statutory auditor or an audit committee is used is not clear from the summaries | Same |
Major Shareholders
| Holder | Shares | Stake (%) | Date | Source |
|---|---|---|---|---|
Curo Holdings and 7 related parties (total) | 8,274,739 | 41.67 | 28-Sep-2026 | WiseReport |
of which Curo Holdings | 15,818,348 (pre-consolidation count) | 20.26 | 16-Apr-2026 | GoInsider |
of which GNCO | 5,589,204 (pre-consolidation count) | 7.16 | 16-Apr-2026 | GoInsider |
of which Q Capital Partners | — | 3.96 | 6-Aug-2026 | GoInsider |
of which Dr. Lee Sang-gyun (CEO) | — | 0.67 | 13-Aug-2026 | GoInsider |
Treasury shares | 40,120 | 0.20 | 28-Sep-2026 | WiseReport |
Foreign investors | — | 0.00 | Oct-2026 | AlphaSquare |
Competitive Landscape
Key Competitors
| Competitor | Positioning vs CreoSG |
|---|---|
Samsung SDS | Large SI prime contractor; also a CreoSG customer (May-2026 contract) |
LG CNS | Major financial-sector SI |
SK AX (formerly SK C&C) | Major SI with financial practice |
Bankware Global (KOSDAQ) | Korean core-banking package vendor; most direct domestic package competitor |
TmaxSoft / Tmax group | Banking frameworks and middleware |
Tata Consultancy Services (TCS BaNCS) | Global core-banking package (same product heritage as BANCS) |
Oracle (FLEXCUBE) | Global core-banking package |
Temenos | Global core-banking package |
Infosys (Finacle) | Global core-banking package |
Merck & Co. | Holds an approved rVSV-vector Ebola (Zaire) vaccine, the main validation of the rVSV approach |
IAVI and Public Health Vaccines | rVSV candidates for Lassa, Marburg, Sudan ebolavirus and Nipah |
Moderna | mRNA platform competing for rapid-response vaccine programmes |
SK bioscience; EuBiologics; GC Biopharma | Korean vaccine developers/manufacturers competing for government programmes |
Competitor Detail
| Metric | CreoSG |
|---|---|
Revenue, latest FY | KRW 10.86 bn (FY2025) |
Revenue growth | 33.15% (FY2025) |
Operating margin | -59.01% (FY2025) |



